SynthesisBMC oral health2025
Exploring the use and efficacy of 5-fluorouracil in the management of odontogenic keratocysts: a systematic review and meta-analysis.
Synthesis in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Odontogenic keratocyst (OKC) is a challenging jaw lesion known for its aggressive behavior and high recurrence rate. Concerns about the safety and effectiveness of existing adjuvant treatments have encouraged the search for safer alternatives such as 5-Fluorouracil (5-FU). This systematic review and meta-analysis evaluated the efficacy of 5-FU as an adjunctive therapy for OKC. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a comprehensive search was conducted in PubMed, Embase, Scopus, and Google Scholar up to August 1, 2024. Eligible studies included OKC cases treated with 5-FU, alone or combined with surgery. Risk of bias was assessed using the Cochrane ROB-2 tool for randomized controlled trials and the Newcastle-Ottawa Scale for cohort studies. Data were pooled using inverse variance weighting, and heterogeneity was evaluated using the I² statistic. Fourteen studies (282 lesions) were included, comprising randomized controlled trials, cohort studies, and case reports of varying quality. Moderate heterogeneity was observed (I² = 37-57%). In five comparative studies, no recurrences occurred in the 5-FU group versus 24.21% in the modified Carnoy's solution (MCS) group (p < 0.001). Postoperative paresthesia as also lower with 5-FU (18.82% vs. 37.89%, p = 0.012). Compared with segmental resection, 5-FU achieved similar recurrence prevention but with much lower morbidity, including fewer permanent sensory deficits (9.09% temporary in 5-FU vs. 100% permanent in segmental resection, p < 0.001). Bone density was significantly higher after 5-FU treatment than with enucleation alone (p < 0.001). No systemic or severe local side effects were reported. 5-FU appears to be a highly promising adjunctive therapy for OKC, offering effective recurrence prevention with minimal morbidity However, current evidence remains limited by small sample sizes, study heterogeneity, and non-randomized designs. Larger, well-designed trials with long-term follow-up are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.